CN101547924B - 抑制有丝分裂的化合物 - Google Patents

抑制有丝分裂的化合物 Download PDF

Info

Publication number
CN101547924B
CN101547924B CN2007800423837A CN200780042383A CN101547924B CN 101547924 B CN101547924 B CN 101547924B CN 2007800423837 A CN2007800423837 A CN 2007800423837A CN 200780042383 A CN200780042383 A CN 200780042383A CN 101547924 B CN101547924 B CN 101547924B
Authority
CN
China
Prior art keywords
cancer
compound
group
cell
benzazepine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2007800423837A
Other languages
English (en)
Chinese (zh)
Other versions
CN101547924A (zh
Inventor
克里斯托弗·F·克莱本
托德·B·塞尔斯
斯蒂芬·G·斯特劳德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39315133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101547924(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Priority to CN201310367332.9A priority Critical patent/CN103483343B/zh
Publication of CN101547924A publication Critical patent/CN101547924A/zh
Application granted granted Critical
Publication of CN101547924B publication Critical patent/CN101547924B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN2007800423837A 2006-11-16 2007-11-14 抑制有丝分裂的化合物 Active CN101547924B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310367332.9A CN103483343B (zh) 2006-11-16 2007-11-14 抑制有丝分裂的化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85934006P 2006-11-16 2006-11-16
US60/859,340 2006-11-16
PCT/US2007/023948 WO2008063525A1 (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201310367332.9A Division CN103483343B (zh) 2006-11-16 2007-11-14 抑制有丝分裂的化合物

Publications (2)

Publication Number Publication Date
CN101547924A CN101547924A (zh) 2009-09-30
CN101547924B true CN101547924B (zh) 2013-09-25

Family

ID=39315133

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2007800423837A Active CN101547924B (zh) 2006-11-16 2007-11-14 抑制有丝分裂的化合物
CN201310367332.9A Active CN103483343B (zh) 2006-11-16 2007-11-14 抑制有丝分裂的化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201310367332.9A Active CN103483343B (zh) 2006-11-16 2007-11-14 抑制有丝分裂的化合物

Country Status (34)

Country Link
US (7) US8026246B2 (enExample)
EP (4) EP2497772B1 (enExample)
JP (3) JP5102839B2 (enExample)
KR (2) KR101110458B1 (enExample)
CN (2) CN101547924B (enExample)
AR (1) AR064246A1 (enExample)
AT (1) ATE556076T1 (enExample)
AU (1) AU2007322046B2 (enExample)
BR (1) BRPI0718803B8 (enExample)
CA (1) CA2669680C (enExample)
CL (1) CL2007003244A1 (enExample)
CR (3) CR10782A (enExample)
CY (1) CY1112828T1 (enExample)
DK (2) DK2086981T3 (enExample)
EA (1) EA015779B1 (enExample)
ES (3) ES2537451T3 (enExample)
GE (1) GEP20125459B (enExample)
HR (2) HRP20120490T1 (enExample)
IL (1) IL198690A0 (enExample)
MA (1) MA30988B1 (enExample)
MX (3) MX348568B (enExample)
MY (1) MY153243A (enExample)
NO (1) NO343338B1 (enExample)
NZ (3) NZ597252A (enExample)
PH (1) PH12012502057B1 (enExample)
PL (2) PL2497772T3 (enExample)
PT (2) PT2086981E (enExample)
RS (2) RS53788B1 (enExample)
SG (2) SG10201503350TA (enExample)
SI (2) SI2497772T1 (enExample)
TW (1) TWI401255B (enExample)
UA (1) UA94129C2 (enExample)
WO (1) WO2008063525A1 (enExample)
ZA (1) ZA200903279B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2299080T3 (es) * 2004-05-14 2008-05-16 Millennium Pharmaceuticals, Inc. Compuestos y metodos para inhibir la progresion mitotica mediante la inhibicion de quinasas aurora.
CL2007003244A1 (es) * 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
WO2010065134A1 (en) * 2008-12-05 2010-06-10 Millennium Pharmaceuticals, Inc. 5, 7-dihydro- 6h-pyrimido [ 5, 4-d] [ 1 ] benzazepin-6-thiones as plk inhibitors
WO2010074724A1 (en) * 2008-12-22 2010-07-01 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd20 antibodies
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
US8653064B2 (en) 2010-02-19 2014-02-18 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin-2-yl]amino}-2-methoxybenzoate
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
WO2011161031A1 (en) * 2010-06-22 2011-12-29 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains
UY34114A (es) 2011-06-03 2013-01-03 Millennium Pharm Inc Combinación de inhibidores de mek e inhibidores selectivos de la quiinasa aurora a
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN103772391A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
US9724354B2 (en) 2013-03-22 2017-08-08 Millennium Pharmaceuticals, Inc. Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
EP3076963A4 (en) 2013-12-06 2017-09-13 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
WO2016106357A1 (en) * 2014-12-23 2016-06-30 Millennnium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
JP2018524292A (ja) 2015-07-21 2018-08-30 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼインヒビターと化学療法剤の投与
CA2997769A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
CN108349961B (zh) 2015-09-09 2022-02-18 西奈山伊坎医学院 杂环受限三环磺酰胺作为抗癌试剂
JP6591036B2 (ja) 2016-02-26 2019-10-16 公益財団法人がん研究会 Ｈｐ１の機能に着目した抗癌剤のスクリーニング方法及び評価系
SG11201807965YA (en) 2016-03-15 2018-10-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors
JP6188986B1 (ja) * 2017-03-23 2017-08-30 株式会社ノエビア 時計遺伝子発現量調整剤及びエラスチン産生促進剤
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
EP4504710A1 (en) 2022-04-07 2025-02-12 Eli Lilly and Company Process for making a kras g12c inhibitor
WO2023196887A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company Method of treatment including kras g12c inhibitors and aurora a inhibitors
US20240108618A1 (en) 2022-06-30 2024-04-04 Eli Lilly And Company Kras g12c inhibitor dosing regimens
WO2025075211A1 (en) 2023-10-03 2025-04-10 Takeda Pharmaceutical Company Limited Alisertib and paclitaxel for treating small cell lung cancer
WO2025245045A1 (en) 2024-05-21 2025-11-27 The Regents Of The University Of California Methods of treating lung cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) * 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
FR2450833A1 (fr) 1979-02-07 1980-10-03 Hoffmann La Roche Derives de benzazepine
US4481142A (en) * 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
US4469633A (en) * 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) * 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) * 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
CN1084747C (zh) * 1996-03-08 2002-05-15 曾尼卡有限公司 作为神经活性剂的吡咯并苯并氮杂䓬衍生物
JP2001507349A (ja) * 1996-12-23 2001-06-05 セルテック セラピューティックス リミテッド 縮合多環式２−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
CN1155599C (zh) * 1997-09-29 2004-06-30 明治制果株式会社 三环三唑并苯并氮杂�衍生物、用于制备该衍生物的方法和抗变态反应剂
US6277844B1 (en) * 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
WO2001042199A1 (en) 1999-12-06 2001-06-14 Ajinomoto Co.,Inc. Amidinophenylpyruvic acid derivative
HUP0400639A3 (en) 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) * 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
BR0211729A (pt) 2001-08-09 2004-08-24 Actelion Pharmaceuticals Ltd Compostos, composições farmacêuticas, processo para fabricar compostos, uso de um ou mais compostos, e, processo para fabricar composições farmacêuticas
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
ES2299080T3 (es) * 2004-05-14 2008-05-16 Millennium Pharmaceuticals, Inc. Compuestos y metodos para inhibir la progresion mitotica mediante la inhibicion de quinasas aurora.
WO2006055831A2 (en) 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Kinase inhibitors
US20100160324A1 (en) 2004-12-30 2010-06-24 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
SI1962830T1 (sl) 2005-12-23 2013-07-31 Glaxosmithkline Llc Azaindolni inhibitorji kinaz Aurora
EP2054413A2 (en) 2006-08-09 2009-05-06 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها

Also Published As

Publication number Publication date
EA015779B1 (ru) 2011-12-30
CL2007003244A1 (es) 2008-04-04
EP2086981A1 (en) 2009-08-12
EP2497772B1 (en) 2014-10-29
CR10782A (es) 2009-06-24
HK1217699A1 (en) 2017-01-20
EP2497773A1 (en) 2012-09-12
JP5452811B2 (ja) 2014-03-26
CR20140154A (es) 2014-07-23
US11958855B2 (en) 2024-04-16
US20110312942A1 (en) 2011-12-22
HRP20150047T1 (en) 2015-03-13
US8026246B2 (en) 2011-09-27
HK1175778A1 (en) 2013-07-12
MX2009004670A (es) 2009-05-15
PT2086981E (pt) 2012-06-20
US9988384B2 (en) 2018-06-05
RS53788B1 (sr) 2015-06-30
CN101547924A (zh) 2009-09-30
SI2497772T1 (sl) 2015-03-31
EP2497773B1 (en) 2015-02-25
NZ597252A (en) 2013-06-28
HK1175777A1 (en) 2013-07-12
KR101342014B1 (ko) 2013-12-19
AU2007322046B2 (en) 2012-04-05
CN103483343A (zh) 2014-01-01
JP5102839B2 (ja) 2012-12-19
HRP20120490T1 (hr) 2012-07-31
NO20091864L (no) 2009-06-15
MA30988B1 (fr) 2009-12-01
TW200829589A (en) 2008-07-16
PT2497772E (pt) 2015-02-05
CA2669680A1 (en) 2008-05-29
US10836766B2 (en) 2020-11-17
CY1112828T1 (el) 2016-02-10
CA2669680C (en) 2012-04-10
AU2007322046A1 (en) 2008-05-29
TWI401255B (zh) 2013-07-11
EP2944639A1 (en) 2015-11-18
KR101110458B1 (ko) 2012-03-13
GEP20125459B (en) 2012-03-26
PH12012502057B1 (en) 2018-10-24
RS52313B (sr) 2012-12-31
US20110312943A1 (en) 2011-12-22
ES2528793T3 (es) 2015-02-12
US20150166545A1 (en) 2015-06-18
KR20090091173A (ko) 2009-08-26
NZ611898A (en) 2015-01-30
JP2012006965A (ja) 2012-01-12
BRPI0718803A2 (pt) 2013-12-03
PL2086981T3 (pl) 2012-09-28
DK2497772T3 (en) 2015-01-19
DK2086981T3 (da) 2012-08-06
US20080167292A1 (en) 2008-07-10
US20240400567A1 (en) 2024-12-05
IL198690A0 (en) 2010-02-17
UA94129C2 (ru) 2011-04-11
HK1134672A1 (en) 2010-05-07
SG176443A1 (en) 2011-12-29
CR20140544A (es) 2015-01-12
CN103483343B (zh) 2016-06-01
SG10201503350TA (en) 2015-06-29
ES2537451T3 (es) 2015-06-08
EA200970486A1 (ru) 2009-10-30
EP2086981B1 (en) 2012-05-02
MX348568B (es) 2017-06-20
MX343391B (es) 2016-11-04
US9765076B2 (en) 2017-09-19
KR20110113210A (ko) 2011-10-14
NZ577042A (en) 2012-03-30
US20210214361A1 (en) 2021-07-15
ATE556076T1 (de) 2012-05-15
MY153243A (en) 2015-01-29
NO343338B1 (no) 2019-02-04
EP2497772A1 (en) 2012-09-12
JP2010510215A (ja) 2010-04-02
BRPI0718803B1 (pt) 2020-11-17
ES2384123T3 (es) 2012-06-29
BRPI0718803B8 (pt) 2021-05-25
AR064246A1 (es) 2009-03-25
PL2497772T3 (pl) 2015-05-29
WO2008063525A1 (en) 2008-05-29
US20190031662A1 (en) 2019-01-31
ZA200903279B (en) 2010-07-28
PH12012502057A1 (en) 2015-09-14
SI2086981T1 (sl) 2012-12-31
JP2014055166A (ja) 2014-03-27
EP2944639B1 (en) 2017-01-04

Similar Documents

Publication Publication Date Title
CN101547924B (zh) 抑制有丝分裂的化合物
ES2900184T3 (es) Combinaciones terapéuticas de un inhibidor de BTK y un inhibidor de BCL-2
CN102803269A (zh) Ampk的噻吩并[2,3-b]嘧啶二酮活化剂及其治疗用途
KR20090130104A (ko) 암 치료를 위한 ｐｉ３ｋ－알파의 억제제로서의 피리도〔２，３­ｄ〕피리미딘­７­온 화합물
JP2009539865A (ja) 置換３−アミノ−チエノ［２，３−ｂ］ピリジン２−カルボン酸アミド化合物及び製造方法及びそれらの使用
CN113620976A (zh) 噻唑并嘧啶类化合物及其制备方法、用途和药物组合物
AU2012203952B2 (en) Compounds for inhibiting mitotic progression
CN118994163A (zh) 含有并环结构的化合物
HK1175777B (en) Compound for inhibiting mitotic progression
HK1217699B (en) Compound for inhibiting mitotic progression
HK1134672B (en) Compounds for inhibiting mitotic progression
AU2014280932A1 (en) Compounds for inhibiting mitotic progression

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant